Cancer Molecular Diagnostics Market Size, CAGR, Trends and Growth Report Forecast 2025–2033

The global Oncology Molecular Diagnostics Market size was valued at USD 4.8 Billion in 2024 and is expected to reach USD 14.3 Billion by 2033. The market is projected to grow at a CAGR of 12.37% during the forecast period 2025–2033. Growth is driven primarily by the rising prevalence of cancer, advancements in molecular diagnostic technologies, and increasing adoption of precision medicine.

Study Assumption Years

• Base Year: 2024

• Historical Years: 2019-2024

• Forecast Period: 2025-2033

Oncology Molecular Diagnostics Market Key Takeaways

• Current Market Size: USD 4.8 Billion (2024)

• CAGR: 12.37%

• Forecast Period: 2025-2033

• The growing geriatric population, changing lifestyles, and increasing smoking trends are major factors driving the rising prevalence of cancer.

• Rapid and accurate diagnosis demand, coupled with advancements in next-generation sequencing (NGS), significantly contribute to market growth.

• Increased viral and bacterial infections along with blood donation campaigns boost demand for oncology molecular diagnostics.

• North America holds a leading market share due to high adoption of advanced diagnostic technologies and personalized medicine.

• Europe is the second largest market, driven by strong regulatory frameworks and growing cancer awareness.

Sample Request Link: https://www.imarcgroup.com/oncology-molecular-diagnostics-market/requestsample

Market Growth Factors

The oncology molecular diagnostics market is driven by the increasing prevalence of cancer. Changing lifestyles, an aging population, and a rising trend in smoking contribute to higher cancer incidence globally. This results in growing demand for molecular diagnostics to enable early and precise detection of various cancers. As the number of cancer cases grows, healthcare systems increasingly rely on molecular diagnostic technologies for better patient outcomes.

Technological advances, especially in next-generation sequencing (NGS) techniques, are key growth enablers. NGS allows rapid sequencing of multiple genes, helping identify mutations essential for cancer diagnosis and personalized treatment. For example, NeoGenomics, Inc. launched the AML Express NGS assay for acute myeloid leukemia in October 2024, highlighting innovation impacts on market expansion.

Additionally, the surge in viral and bacterial infections worldwide and increased participation in blood donation campaigns have heightened the need for oncology molecular diagnostics. These factors underscore the expanding role of molecular diagnostics beyond cancer detection, increasing the overall market demand globally.

Market Segmentation

Breakup by Cancer Type:

• Breast Cancer

• Prostate Cancer

• Colorectal Cancer

• Cervical Cancer

• Liver Cancer

• Lung Cancer

• Blood Cancer

• Others

The report covers various cancer types with breast cancer being highly prevalent, especially among women. Increased colorectal cancer cases in younger populations and the link between HPV infection and cervical cancer further drive demand for molecular diagnostics.

Breakup by Product:

• Instruments

• Reagents

• Others

Instruments like NGS and PCR systems are critical for early detection and treatment monitoring, while continually rising cancer diagnoses increase demand for reagents such as enzymes and primers needed for diagnostic tests.

Breakup by Technology:

• Polymerase Chain Reaction (PCR)

• In Situ Hybridization

• Chips and Microarrays

• Isothermal Nucleic Acid Amplification Technology (INAAT)

• Mass Spectrometry

• DNA and NGS Sequencing

• Transcription Mediated Amplification (TMA)

• Others

PCR is widely used for identifying mutations such as KRAS, EGFR, and BRAF, while ISH techniques detect gene amplifications important in cancers like breast cancer. Microarrays assist in gene expression profiling, aiding cancer biology understanding.

Breakup by End-User:

• Hospitals and Clinics

• Reference Laboratories

• Others

Hospitals and clinics adopt molecular diagnostic tools for early stage cancer detection, while reference laboratories provide high throughput advanced testing services creating consistent demand.

Breakup by Region:

• North America (United States, Canada)

• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa

The market spans globally with detailed country-level analysis. North America leads, driven by high cancer rates and advanced healthcare infrastructure.

Regional Insights

North America is the dominant region in the oncology molecular diagnostics market, owing to the widespread adoption of advanced diagnostic technologies and personalized medicine approaches. The United States, in particular, shows high cancer incidence rates which drive strong demand for molecular diagnostics. Europe is the second-largest market, supported by robust regulatory frameworks and national cancer screening programs. Meanwhile, Asia-Pacific is witnessing increasing cancer cases due to aging populations and urbanization, rising market opportunities.

Recent Developments & News

• October 2024: Qiagen launched the QIAcuityDx Digital PCR System, expanding its digital PCR technology for clinical oncology in North America and the EU.

• October 2024: NeoGenomics, Inc. released AML Express, an NGS assay providing rapid genetic profiling for acute myeloid leukemia patients.

• September 2024: Variantyx introduced Genomic Unity® 2.0, a whole genome diagnostic test combining short- and long-read genome sequencing to detect genetic variations.

Key Players

• Abbott Laboratories

• Amadix

• Cepheid

• F. Hoffmann-La Roche Ltd

• Hologic, Inc.

• Illumina, Inc.

• NeoGenomics Laboratories

• Qiagen N.V.

• Thermo Fisher Scientific Inc.

• Veracyte Inc.

Get Custom Market Research Report for Your Business:

https://www.imarcgroup.com/request?type=report&id=2396&flag=E

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302